[Market Focus] Adbiotech Hits Upper Limit on News of Efficacy Confirmed for Low-Pathogenic Avian Influenza Antibody Treatment

On the morning of January 16, Adbiotech, a company specializing in immune antibodies, hit the upper price limit in early trading. The surge in buying appears to be driven by news confirming the efficacy of its low-pathogenic avian influenza (AI) antibody treatment.

As of 10:18 a.m. on the same day, Adbiotech shares were trading at 2,430 won on the KOSDAQ market, up 29.95% from the previous trading day. The stock opened at 1,872 won and continued to climb throughout the session.

On this day, Adbiotech announced that it had confirmed the efficacy of oral administration of 'Anti-H9 ScFv,' a preventive and therapeutic antibody for low-pathogenic AI of the Y280 lineage, H9N2 type. Anti-H9 ScFv is a single-chain antibody (scFv)-based substance designed to induce an immediate immune response at the early stage of infection by directly administering pre-formed antibodies into the body.

This efficacy evaluation was conducted by adding Anti-H9 ScFv to the feed of laying hens for oral administration, then analyzing changes in antibody response to the H9 AI virus antigen. The level of antibody production was measured using enzyme-linked immunosorbent assay (ELISA) before administration, at two weeks, and at four weeks after administration.

The results showed an increase in blood antibody levels at two weeks after administration, and at four weeks, antibody levels were approximately 30-40% higher than before administration. The oral administration of Anti-H9 ScFv was found to stimulate the immune system of chickens, increasing the production of Anti-H9 antibodies in response to the H9 AI virus, and demonstrated an immune-enhancing effect against the H9 antigen.